SAREPTA THERAPEUTICS, INC. Accrued Liabilities, Current
SAREPTA THERAPEUTICS, INC. (SRPT) had Accrued Liabilities, Current of $325.23 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current › Accrued Liabilities, Current
us-gaap:AccruedLiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Accrued Liabilities, Current $325.23M.
- 2026-03-31: Accrued Liabilities, Current $302.37M.
- 2025-12-31: Accrued Liabilities, Current $359.66M.
- 2025-09-30: Accrued Liabilities, Current $295.79M.
| Period end | Accrued Liabilities, Current |
|---|---|
| 2026-06-30 | $325.23M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $302.37M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $359.66M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $295.79M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $377.40M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $391.65M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $373.51M 10-K · filed 2026-03-02 |
| 2024-09-30 | $344.83M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $350.40M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $283.32M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $315.00M 10-K · filed 2025-02-28 |
| 2023-09-30 | $322.35M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $326.88M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $345.55M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $419.00M 10-K · filed 2024-02-28 |
| 2022-09-30 | $369.00M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $383.70M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $293.91M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $271.70M 10-K · filed 2023-02-28 |
| 2021-09-30 | $221.01M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $240.14M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $180.64M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $193.55M 10-K · filed 2022-03-01 |
| 2020-09-30 | $199.06M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $159.09M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $176.30M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $185.53M 10-K · filed 2021-03-01 |
| 2019-09-30 | $121.66M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $107.33M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $100.12M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $134.09M 10-K · filed 2020-02-26 |
| 2018-09-30 | $88.69M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $72.48M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $65.65M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $68.98M 10-K · filed 2019-02-28 |
| 2017-09-30 | $55.75M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $39.18M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $31.16M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $31.02M 10-K · filed 2018-03-01 |
| 2016-09-30 | $29.54M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $35.06M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $24.28M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $29.05M 10-K · filed 2017-02-28 |
| 2015-09-30 | $19.76M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $15.18M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $15.04M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $17.37M 10-K · filed 2016-02-25 |
| 2014-09-30 | $14.82M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $13.84M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $16.34M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $14.60M 10-K · filed 2015-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |